SIGA Q1 2026 revenue falls to $6.2 million as net loss widens to $3.5 million
SIGA Technologies reported first-quarter 2026 total revenues of $6.2 million, down from $7.0 million a year earlier, and a net loss of $3.5 million, compared with $0.4 million in the first quarter of 2025. Management said it expects to deliver more than $35 million of oral and IV TPOXX to the U.S. government and an international customer across the second and third quarters of 2026, which is the main near-term revenue driver the company cited.
Key points
- Total revenues were $6.2 million for the three months ended March 31, 2026, versus $7.0 million a year earlier.
- Product sales fell to $3.5 million from $5.8 million, while research and development revenues rose to $2.7 million from $1.2 million.
- Net loss was $3.5 million, or $0.05 per diluted share, compared with a net loss of $0.4 million, or $0.01 per diluted share.
- About $13 million of oral TPOXX is planned for delivery to an Asia Pacific customer in the second quarter of 2026, and about $26 million of IV TPOXX to the U.S. Strategic National Stockpile by the end of the third quarter.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.